Klaus Pantel

Klaus Pantel's AcademicInfluence.com Rankings

Klaus Pantel

Philosophy

#2487

World Rank

#4235

Historical Rank

Logic

#607

World Rank

#1082

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Klaus Pantel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Klaus Pantel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tumour exosome integrins determine organotropic metastasis (2015) (3223)
Cell-free nucleic acids as biomarkers in cancer patients (2011) (2382)
A pooled analysis of bone marrow micrometastasis in breast cancer. (2005) (1290)
Dissecting the metastatic cascade (2004) (1290)
Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System (2007) (1194)
Detection, clinical relevance and specific biological properties of disseminating tumour cells (2008) (1099)
Challenges in circulating tumour cell research (2014) (1055)
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. (2016) (981)
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. (2000) (939)
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay (2013) (926)
Clinical relevance of circulating cell-free microRNAs in cancer (2014) (890)
PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation to promote metastasis (2014) (759)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. (2014) (684)
In vitro differentiation of endothelial cells from AC133-positive progenitor cells. (1999) (681)
Tumor metastasis: moving new biological insights into the clinic (2013) (656)
Circulating tumor cells: liquid biopsy of cancer. (2013) (613)
Circulating tumour cells in cancer patients: challenges and perspectives. (2010) (592)
Liquid biopsy and minimal residual disease — latest advances and implications for cure (2019) (529)
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients (2014) (517)
In vitro differentiation of endothelial cells from AC133-positive progenitor cells (2000) (514)
Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. (1993) (508)
Detection and clinical importance of micrometastatic disease. (1999) (505)
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. (2013) (494)
Circulating tumor cells and circulating tumor DNA. (2012) (493)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial (2010) (468)
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. (1999) (456)
Biology, detection, and clinical implications of circulating tumor cells (2014) (449)
Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. (1996) (437)
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. (2011) (426)
[The circulating tumor cells: liquid biopsy of cancer]. (2014) (415)
Cancer micrometastases (2009) (413)
Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases (1996) (412)
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer (2010) (409)
Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity (2005) (401)
Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. (2000) (393)
The biology of circulating tumor cells (2016) (385)
Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. (1997) (375)
Liquid Biopsies, What We Do Not Know (Yet). (2017) (371)
Real-time liquid biopsy in cancer patients: fact or fiction? (2013) (369)
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. (2013) (367)
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape (2017) (365)
Data Normalization Strategies for MicroRNA Quantification. (2015) (362)
Corrigendum: PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis (2014) (351)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial (2010) (344)
Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer (2012) (334)
Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. (1994) (321)
Considerations in the development of circulating tumor cell technology for clinical use (2012) (313)
Clinical utility of circulating non-coding RNAs — an update (2018) (307)
Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells (2005) (307)
Establishment and characterization of a cell line from human circulating colon cancer cells. (2015) (306)
Review: Biological relevance of disseminated tumor cells in cancer patients (2008) (306)
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing (2013) (305)
Frequent expression of PD‐L1 on circulating breast cancer cells (2015) (301)
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells (2019) (297)
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. (1997) (295)
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. (1999) (286)
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer (2016) (280)
Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. (1998) (274)
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients (2014) (268)
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. (2013) (260)
Controversies in clinical cancer dormancy (2011) (253)
Hematogenous dissemination of glioblastoma multiforme (2014) (252)
Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer (2012) (250)
ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy (2011) (248)
Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer (2009) (246)
Cancer stem cells: The root of tumor recurrence and metastases. (2017) (245)
Circulating Tumor Cells and Bone Marrow Micrometastasis (2008) (240)
Molecular signature associated with bone marrow micrometastasis in human breast cancer. (2003) (239)
Circulating epithelial cells in patients with benign colon diseases. (2012) (239)
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation (2006) (233)
Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. (2005) (225)
Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis (2011) (223)
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. (1991) (223)
Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. (2013) (220)
Technologies for detection of circulating tumor cells: facts and vision. (2014) (220)
High incidence of EMMPRIN expression in human tumors (2006) (217)
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. (2013) (213)
Breast cancer brain metastases: biology and new clinical perspectives (2016) (209)
Plasticity of disseminating cancer cells in patients with epithelial malignancies (2012) (208)
Liquid Biopsy: From Discovery to Clinical Application. (2021) (206)
Circulating tumor cell isolation and diagnostics: toward routine clinical use. (2011) (200)
Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma (2013) (200)
p53 and K-RAS alterations in pancreatic epithelial cell lesions. (1993) (198)
Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. (1999) (198)
Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. (1994) (196)
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. (2001) (196)
Detection and characterization of putative metastatic precursor cells in cancer patients. (2007) (195)
Capture of viable circulating tumor cells in the liver of colorectal cancer patients. (2013) (194)
Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. (1999) (192)
Prognostic significance of bone marrow micrometastases in patients with gastric cancer. (1996) (189)
Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells (2006) (186)
Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. (2013) (186)
Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. (1991) (182)
Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer (2016) (178)
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence (2005) (176)
Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. (1993) (176)
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study (2012) (176)
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. (2013) (176)
Radical systematic mediastinal lymphadenectomy in non‐small cell lung cancer: A randomized controlled trial (1994) (173)
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis (2018) (173)
Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells. (2018) (173)
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. (2019) (172)
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors (2002) (172)
Cancer micrometastasis and tumour dormancy (2008) (171)
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. (2012) (171)
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer (2009) (170)
Biologic challenges in the detection of circulating tumor cells. (2013) (167)
Detection and Monitoring of Cell‐Free DNA in Blood of Patients with Colorectal Cancer (2008) (167)
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer (2013) (163)
Liquid Biopsy: Current Status and Future Perspectives (2017) (160)
Clinical applications of the CellSearch platform in cancer patients. (2018) (158)
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond (2020) (158)
Profiling circulating tumour cells and other biomarkers of invasive cancers (2018) (155)
Clinical relevance and biology of circulating tumor cells (2011) (153)
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients (2012) (147)
Expression of Extracellular Matrix Metalloproteases Inducer on Micrometastatic and Primary Mammary Carcinoma Cells (2004) (146)
Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. (1999) (144)
Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells (2012) (142)
Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis (2014) (141)
A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells (2016) (140)
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions (2013) (140)
Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. (2000) (138)
Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. (2003) (138)
Down-Regulated Expression of Cytokeratin 18 Promotes Progression of Human Breast Cancer (2004) (138)
Molecular mechanisms of metastasis (2011) (135)
MAGE-A gene expression pattern in primary breast cancer. (2001) (133)
Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells (2015) (131)
Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. (1995) (129)
Tumor–antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease (1999) (128)
Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. (2016) (127)
miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes. (2018) (125)
Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. (1995) (123)
Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. (2017) (123)
The dynamic range of circulating tumor DNA in metastatic breast cancer (2014) (123)
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ (2011) (122)
Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. (1996) (121)
Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients (2013) (120)
Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. (2016) (120)
Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. (2015) (117)
Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. (1996) (114)
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer (2012) (114)
Circulating tumor cells as therapy-related biomarkers in cancer patients (2013) (114)
The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study (2011) (113)
Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity (2013) (111)
Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer* (2013) (111)
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial (2014) (110)
Circulating tumour‐associated plasma DNA represents an independent and informative predictor of prostate cancer (2006) (110)
Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. (2014) (109)
Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients (2015) (109)
Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. (1996) (109)
Biology and clinical relevance of EpCAM (2019) (108)
Detection of circulating tumour cells in peripheral blood of patients with advanced non‐metastatic bladder cancer (2011) (107)
Genomic Profiling of Viable and Proliferative Micrometastatic Cells from Early-Stage Breast Cancer Patients (2004) (104)
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial (2018) (104)
Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. (1996) (102)
Disseminated Tumor Cells in Bone Marrow and Circulating Tumor Cells in Blood of Breast Cancer Patients: Current State of Detection and Characterization (2008) (102)
Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. (2019) (101)
Epithelial-mesenchymal plasticity in circulating tumor cells (2017) (101)
Tumor cell dormancy: An NCI workshop report (2007) (101)
Prognostic impact of matrix metalloproteinase‐9 in operable non‐small cell lung cancer (2003) (100)
Tumor signatures in the blood (2014) (99)
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer (2011) (98)
Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. (1999) (95)
Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion (2009) (95)
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients (2016) (95)
Relevance of PTEN loss in brain metastasis formation in breast cancer patients (2012) (94)
Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells (2010) (93)
Exosomal microRNAs as tumor markers in epithelial ovarian cancer (2018) (93)
Liquid biopsies: Potential and challenges (2020) (93)
Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients (2015) (93)
Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. (1996) (92)
Circulating DNA as biomarker in breast cancer (2015) (92)
Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. (2000) (91)
Circulating Tumors Cells as Biomarkers: Progress Toward Biomarker Qualification (2011) (90)
Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. (2010) (89)
Functional Studies on Viable Circulating Tumor Cells. (2016) (89)
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance (2008) (89)
Circulating tumor cells detection has independent prognostic impact in high‐risk non‐muscle invasive bladder cancer (2014) (88)
The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence (2001) (87)
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors (2019) (86)
Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. (2014) (86)
L1 is associated with micrometastatic spread and poor outcome in colorectal cancer (2007) (86)
Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. (2010) (86)
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. (2008) (85)
Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression (2011) (84)
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. (2018) (84)
RT‐PCR‐Based Detection of Occult Disseminated Tumor Cells in Peripheral Blood and Bone Marrow of Patients with Solid Tumors: An Overview (2000) (84)
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer. (2015) (83)
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. (2011) (83)
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? (2019) (83)
Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. (2001) (82)
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment (2008) (82)
The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC‐γ1 signalling in breast cancer cell migration and dissemination (2012) (82)
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. (2003) (82)
Characterization of different CTC subpopulations in non-small cell lung cancer (2016) (82)
Micrometastatic bone marrow involvement: detection and prognostic significance (1999) (81)
Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. (2002) (79)
Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. (2001) (78)
Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? (2016) (78)
Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. (2019) (77)
Liquid biopsies (2019) (77)
A mathematical model of erythropoiesis in mice and rats Part 1: Structure of the model (1989) (77)
Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors (2012) (77)
Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. (1995) (76)
Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. (2002) (76)
Detection and clinical relevance of micrometastatic cancer cells (2000) (76)
Detection and measurement of occult disease for the prognosis of solid tumors. (2003) (74)
Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases (2014) (73)
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial (2017) (73)
Advances in liquid biopsy approaches for early detection and monitoring of cancer (2018) (73)
Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. (2003) (73)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients (2015) (73)
Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer (2016) (72)
Impact of platinum‐based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients (2011) (71)
Detection and characterization of residual disease in breast cancer. (1994) (71)
Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression (2012) (70)
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients (2016) (70)
Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. (1995) (70)
Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer (2015) (70)
Interplay of lncRNA H19/miR‐675 and lncRNA NEAT1/miR‐204 in breast cancer (2019) (70)
Liquid biopsy: Potential and challenges (2016) (70)
Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer (2003) (69)
Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. (2016) (69)
Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours (2019) (69)
Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients (2014) (68)
Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. (2018) (68)
Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer (2004) (67)
Current status in human breast cancer micrometastasis (2007) (67)
Genome-wide microarray gene expression, array-CGH analysis, and telomerase activity in advanced ovarian endometriosis: a high degree of differentiation rather than malignant potential. (2008) (67)
A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. (1995) (66)
High‐resolution genomic profiling of occult micrometastatic tumor cells (2003) (65)
Detection of tumor‐specific DNA in blood and bone marrow plasma from patients with prostate cancer (2007) (65)
Definition of molecular determinants of prostate cancer cell bone extravasation. (2013) (65)
Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer (2018) (65)
Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response. (2015) (64)
BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood (2010) (64)
Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity (2020) (63)
Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. (2008) (63)
Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. (2018) (62)
Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. (1998) (62)
Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. (2010) (61)
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. (2013) (61)
In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. (2018) (59)
Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. (2009) (59)
Functional studies on circulating and disseminated tumor cells in carcinoma patients (2016) (58)
Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients (2018) (58)
Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes (2018) (58)
Pathology: Are circulating tumor cells predictive of overall survival? (2009) (58)
Micrometastases in Bone Marrow: Prognostic Indicators for Pancreatic Cancer (1999) (57)
Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. (1995) (57)
Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression (2010) (57)
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer (2009) (57)
Strong Impact of Micrometastatic Tumor Cell Load in Patients with Esophageal Carcinoma (2009) (56)
Rationale and Design of the Hamburg City Health Study (2019) (55)
Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells (2016) (55)
ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients (2012) (55)
Detection and Characterization of Circulating Microsatellite‐DNA in Blood of Patients with Breast Cancer (2004) (55)
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022) (55)
Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients? (2019) (55)
EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients (2019) (53)
Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the alpha 1-adrenergic positive inotropic effect in human atrium. (2005) (53)
Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection (2016) (53)
p53 gene mutations are not required for early dissemination of cancer cells. (1999) (53)
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial (2018) (53)
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program (2015) (53)
Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. (2011) (53)
Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. (2005) (53)
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. (2019) (52)
Detection of minimal disease in patients with solid tumors. (1996) (52)
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2‐negative metastatic breast cancer (2016) (52)
High‐resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer (2012) (52)
Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B (2017) (51)
The clinical significance of circulating tumor cells (2007) (51)
Expression and prognostic significance of immunoregulatory molecules in esophageal cancer (1997) (51)
Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial (2008) (51)
Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients (2010) (51)
Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection (2017) (51)
Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation (1997) (50)
Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. (1994) (50)
Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters (2007) (50)
Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest® (2016) (50)
Micrometastasis in breast cancer and other solid tumors. (2004) (50)
Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile. (2009) (49)
Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer (2015) (49)
International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (49)
A mathematical model of erythropoiesis in mice and rats Part 2: Stimulated erythropoiesis (1989) (49)
Characterization of single circulating tumor cells (2017) (49)
Comparative evaluation of urokinase‐type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells (2003) (49)
Determination of PD-L 1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1 / PD-L 1 Inhibitors (2019) (48)
Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer (2017) (48)
Novel approaches to target the microenvironment of bone metastasis (2021) (48)
Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay (2015) (47)
Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis (2007) (47)
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer (2011) (47)
Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. (2008) (47)
Circulating Tumor Cells in Patients with Testicular Germ Cell Tumors (2014) (46)
Combined PET/MRI: Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany (2017) (46)
Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer (2012) (46)
Clonality of circulating tumor cells in breast cancer brain metastasis patients (2019) (45)
Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. (2016) (45)
Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer (2018) (45)
Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. (2005) (44)
Comparison of Genetic Alterations Detected in Circulating Microsatellite DNA in Blood Plasma Samples of Patients with Prostate Cancer and Benign Prostatic Hyperplasia (2006) (44)
Disseminierte Tumorzellen: Diagnostik, prognostische Relevanz, Phänotypisierung und therapeutische Strategien (1997) (44)
International liquid biopsy standardization alliance white paper. (2020) (44)
Disseminated Tumor Cells in Bone Marrow and the Natural Course of Resected Esophageal Cancer (2012) (44)
Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. (1996) (44)
Epigenetic Analysis of Body Fluids and Tumor Tissues (2006) (43)
COMMENT ON : MICROMETASTATIC BREAST CANCER CELLS IN BONE MARROW AT PRIMARYSURGERY : PROGNOSTIC VALUE IN COMPARISON WITH NODAL STATUS. AUTHORS' REPLY (1998) (43)
Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. (1996) (43)
Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance. (2003) (42)
Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. (2006) (42)
Molecular mechanisms of metastasis (2006) (42)
Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer (2008) (41)
Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. (2013) (41)
Mode of Spread in the Early Phase of Lymphatic Metastasis in Pancreatic Ductal Adenocarcinoma: Prognostic Significance of Nodal Microinvolvement (2004) (41)
Squamous cell carcinoma of the oral cavity and circulating tumour cells. (2014) (41)
The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. (2012) (40)
What's new on circulating tumor cells? A meeting report (2010) (40)
Clinical significance of occult metastatic cells in bone marrow of breast cancer patients. (2001) (40)
p53 in non-small-cell lung cancer. (1994) (39)
Prognostic significance of micrometastatic bone marrow involvement (2004) (38)
AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. (2014) (38)
CXCR7 expression in esophageal cancer (2013) (38)
Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer (1999) (37)
Micrometastasis detection and treatment with monoclonal antibodies. (1996) (37)
Tracking tumor resistance using 'liquid biopsies' (2013) (37)
A European interlaboratory testing of three well‐known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow (2006) (37)
Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. (2016) (37)
Quantitative High-Resolution Genomic Analysis of Single Cancer Cells (2011) (37)
Biological Characteristics of Micrometastatic Cancer Cells in Bone Marrow (1999) (37)
A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer (2007) (37)
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial (2017) (36)
Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2. (2015) (36)
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease (2018) (36)
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma (2014) (36)
Detection methods of circulating tumor cells. (2012) (35)
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern (2011) (35)
Plasma microRNA signature is associated with risk stratification in prostate cancer patients (2017) (35)
A Versatile Microarray Platform for Capturing Rare Cells (2015) (35)
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia (2016) (35)
Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients (2014) (35)
Clinical relevance of cytoskeleton associated proteins for ovarian cancer (2018) (34)
Disseminated tumor cells in pancreatic cancer—an independent prognosticator of disease progression and survival (2012) (34)
Recent translational research: circulating tumor cells in breast cancer patients (2006) (34)
Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue (2011) (34)
Detection of MAGE-A Transcripts in Bone Marrow Is an Independent Prognostic Factor in Operable Non–Small-Cell Lung Cancer (2007) (34)
Heterogeneity of miR-10b expression in circulating tumor cells (2015) (34)
15‐Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial–mesenchymal transition, and promotes cell migration in cultured breast cancer cells (2012) (34)
Disseminated breast tumour cells: biological and clinical meaning (2018) (33)
A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy (2017) (33)
Lymphatic spread and microinvolvement in adenocarcinoma of the esophago‐gastric junction (2006) (33)
Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region. (1995) (33)
Tumour microenvironment: informing on minimal residual disease in solid tumours (2017) (33)
Opposite roles of FOXA1 and NKX2‐1 in lung cancer progression (2012) (32)
Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications (2010) (32)
The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications (2012) (32)
Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. (2020) (32)
MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods (2020) (32)
Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells (2004) (31)
Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells. (2017) (31)
Early metastasis of human solid tumours: expression of cell adhesion molecules. (1995) (31)
Liquid biopsy: novel technologies and clinical applications (2018) (31)
A mathematical model of erythropoiesis in mice and rats. Part 4: Differences between bone marrow and spleen (1990) (31)
Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells. (2000) (31)
Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives (2004) (31)
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm (2015) (30)
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. (2021) (30)
Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer (2004) (30)
The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. (2012) (29)
Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases (2017) (29)
PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression (2016) (29)
Circulating tumor cells in head and neck cancer: clinical impact in diagnosis and follow-up (2013) (29)
Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining. (1996) (29)
The role of lymphoid cells in hematopoietic regulation. (1993) (29)
Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer (2020) (29)
Tumorigenic potential of apparently tumor-free lymph nodes. (1999) (29)
Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients (2011) (28)
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions (2021) (28)
Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer (2016) (28)
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer (2018) (28)
Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out? (2009) (27)
Clinical prospects of liquid biopsies (2017) (27)
Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. (2013) (27)
Circulating giant tumor-macrophage fusion cells are independent prognosticators in non-small cell lung cancer patients. (2020) (27)
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs (2015) (27)
Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus (2003) (27)
ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium (2020) (27)
Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. (2003) (26)
Cell lines from circulating tumor cells (2015) (26)
Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas. (2016) (26)
Insulin‐like growth factor‐1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus (2010) (26)
A mathematical model of erythropoiesis in mice and rats Part 3: Suppressed erythropoiesis (1989) (26)
Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application. (2019) (25)
The Interrelating Dynamics of Hypoxic Tumor Microenvironments and Cancer Cell Phenotypes in Cancer Metastasis (2012) (25)
Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19 (1997) (25)
Relevance of βGal–βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients (2015) (25)
Immunocytochemical detection of isolated epithelial tumor cells in bone marrow of patients with pancreatic carcinoma. (1996) (25)
Patterns of metastatic spread in early breast cancer. (2013) (25)
Bispecific single‐chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity (2001) (24)
Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. (2017) (24)
Clinical Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association with Loss of PRKCDBP Expression in Brain Metastases (2012) (24)
Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial. (2018) (24)
Functional activity of RLIM/Rnf12 is regulated by phosphorylation-dependent nucleocytoplasmic shuttling (2013) (24)
A New Era in Liquid Biopsy: From Genotype to Phenotype. (2019) (24)
Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer (2018) (23)
Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients (2019) (23)
Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy (2017) (23)
The 17‐1A antigen is expressed on primary, metastatic and disseminated non‐small cell lung carcinoma cells (2000) (23)
The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer (2018) (22)
Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC) (2020) (22)
Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer. (2014) (22)
Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression (2015) (22)
Identification of HERC5 and its potential role in NSCLC progression (2015) (22)
Methods for Detection of Micrometastatic Carcinoma Cells in Bone Marrow, Blood and Lymph Nodes (1995) (22)
Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients (2020) (22)
Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer (1997) (21)
Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays (2019) (21)
Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy. (2003) (21)
Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer (2016) (21)
Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients (2007) (21)
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial‐mesenchymal transition in cultured breast cancer cells (2017) (20)
Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial. (2019) (20)
Diverse expression patterns of the EMT suppressor grainyhead‐like 2 (GRHL2) in normal and tumour tissues (2016) (20)
Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. (2016) (20)
Molecular determinants of occult metastatic tumor cells in bone marrow. (2001) (20)
Genetic traits for hematogeneous tumor cell dissemination in cancer patients (2016) (19)
Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. (2019) (19)
In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy (2019) (19)
Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. (2003) (19)
Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—A translational project of the German Breast Group study GeparQuattro (2007) (19)
Metabolic regulation of prostate cancer heterogeneity and plasticity. (2020) (19)
Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade (2022) (19)
Mutant p53 promotes epithelial‐mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP‐T mice (2015) (19)
Do Circulating Tumor Cells Have a Role in Deciding on Adjuvant Chemotherapy After Radical Cystectomy? (2015) (18)
RHAMM splice variants confer radiosensitivity in human breast cancer cell lines (2016) (18)
Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray Platform (2020) (18)
Catch and Release: rare cell analysis from a functionalised medical wire (2017) (18)
High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors (2020) (18)
Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study (2019) (18)
Influence of immunomagnetic enrichment on gene expression of tumor cells (2005) (18)
Biological characteristics of micrometastatic carcinoma cells in bone marrow. (1996) (18)
Prospective Comparison of the Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of a Single Patient's Cohort With Esophageal Cancer. (2019) (17)
Supersensitive PSA-Monitored Neoadjuvant Hormone Treatment of Clinically Localized Prostate Cancer: Effects on Positive Margins, Tumor Detection and Epithelial Cells in Bone Marrow (1998) (17)
Low‐grade and high‐grade mammary carcinomas in WAP‐T transgenic mice are independent entities distinguished by Met expression (2013) (17)
Micrometastasis in solid epithelial tumors: impact on surgical oncology. (2002) (17)
EGFR as a stable marker of prostate cancer dissemination to bones (2020) (17)
Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. (2017) (16)
Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein (2014) (16)
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) (16)
Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. (2019) (16)
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. (2018) (16)
Effects of Whole Body Hyperthermia (41.8°C) on the Frequency of Tumor Cells in the Peripheral Blood of Patients with Advanced Malignancies (2003) (16)
Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. (2006) (16)
Cross‐reactive staining of normal bone‐marrow cells by monoclonal antibody 2E11 (1999) (16)
Cancer: Hematogenous dissemination of glioblastoma multiforme (2014) (16)
Current and Future Clinical Applications of ctDNA in Immuno-Oncology (2021) (16)
BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells (2018) (16)
CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis (2021) (16)
Disseminated tumor cells in breast cancer: detection, characterization and clinical relevance. (2006) (15)
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer - A multi-center validation study of the CellSearch™ system. (2006) (15)
HER2-targeted therapy influences CTC status in metastatic breast cancer (2020) (15)
Disseminated tumor cells: diagnosis, prognostic relevance, and phenotyping. (2001) (15)
Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. (2017) (15)
Characterization of circulating DNA in plasma of patients after allogeneic bone grafting (2019) (15)
Pre‐analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients (2020) (15)
Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. (2021) (15)
Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape (2020) (15)
Abstract S2-03: Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis – Results from the adjuvant SUCCESS A trial (2016) (15)
Circulating tumor-derived biomarkers in lung cancer. (2012) (15)
A mathematical model of erythropoiesis suggests an altered plasma volume control as cause for anemia in aged mice (1990) (15)
A Comparative Study of Tissue Inhibitor of Metalloproteinases-1 Levels in Plasma and Tumour Tissue from Patients with Primary Breast Cancer and in Plasma from Patients with Metastatic Breast Cancer (2008) (15)
Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells (2015) (14)
Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer (2017) (14)
Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients. (2018) (14)
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation (2022) (14)
Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients (2009) (14)
ALDH1‐positive intratumoral stromal cells indicate differentiated epithelial‐like phenotype and good prognosis in prostate cancer (2019) (13)
Prostate cancer: Circulating tumour cells in prostate cancer (2018) (13)
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial (2016) (13)
Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases (2018) (13)
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment (2018) (13)
Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method (2020) (13)
Immunodiagnosis and immunotherapy of isolated tumor cells disseminated to bone marrow of patients with colorectal cancer. (1995) (13)
Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer (2019) (13)
Short tandem repeat polymorphism in exon 4 of esophageal cancer-related gene 2 detected in genomic DNA is a prognostic marker for esophageal cancer. (2007) (13)
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2‐negative, Hormone Receptor‐positive Early Breast Cancer (2017) (13)
DETECT III: A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC). (2012) (13)
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. (2021) (13)
Plasma S100P level as a novel prognostic marker of metastatic breast cancer (2016) (12)
Abstract PD04-06: Changes in Circulating Tumor and Endothelial Cells in Peripheral Blood of Patients Treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study “GeparQuinto” (2010) (12)
Molecular analysis of the polymorphisms of thymidylate synthase on cell‐free circulating DNA in blood of patients with advanced colorectal carcinoma (2010) (12)
Evaluation of grafts for occult tumor cells. (1994) (12)
Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients (2003) (12)
Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer (2020) (12)
Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. (2006) (12)
Circulating cancer cells and their clinical applications. (2011) (12)
Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. (2021) (12)
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. (2017) (12)
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019) (12)
In Vitro Modeling of Reoxygenation Effects on mRNA and Protein Levels in Hypoxic Tumor Cells upon Entry into the Bloodstream (2020) (11)
Characterization of disseminated tumor cells. (2001) (11)
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study (2012) (11)
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. (2021) (11)
HER2 as marker for the detection of circulating tumor cells (2009) (11)
Lymphoid cell regulation of hematopoiesis. (1989) (11)
Micrometastatic tumour cells in bone marrow in colorectal cancer (1993) (11)
Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy (2017) (11)
Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study (2017) (11)
Clinical management and biology of tumor dormancy in breast cancer. (2021) (11)
Persistence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients predicts increased risk for relapse-Results of pooled European data. (2006) (11)
Biological labels: Here comes the spaser. (2017) (11)
Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells. (2015) (10)
Immunocytochemical and molecular strategies for the detection of micrometastases in patients with solid epithelial tumours: a review. (1998) (10)
C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC. (2013) (10)
Hunting down the seminal cells of clinical metastases. (1999) (10)
Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer. (2015) (10)
Chronic UVB-irradiation actuates perpetuated dermal matrix remodeling in female mice: Protective role of estrogen (2016) (10)
Detection and relevance of immunohistochemically identifiable tumor cells in lymph nodes. (2000) (10)
Vascular Endothelial Growth Factor Receptor 2 Gene Polymorphisms as Predictors for Tumor Recurrence and Overall Survival in Non-Small-Cell Lung Cancer (2012) (9)
[Disseminated tumor cells: diagnosis, prognostic relevance, phenotyping and therapeutic strategies]. (1997) (9)
Identification and characterisation of minimal residual disease in solid tumors. (2000) (9)
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer (2021) (9)
Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer (2018) (9)
BRCA 1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood (2010) (9)
Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients (2011) (9)
Methylation-Specific PCR for DNA-Based Detection of Occult Tumor Cells in Lymph Nodes of Prostate Cancer Patients (2003) (9)
Stem cell recovery from cyclophosphamide‐induced myelosuppression requires the presence of CD4+ cells (1990) (9)
Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels (2021) (9)
First international ISHAGE symposium on minimal residual cancer. (1996) (9)
Keratin expression reveals mosaic differentiation in vaginal epithelium. (1993) (9)
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer (2018) (9)
Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses (2022) (9)
Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer (2021) (9)
Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases (2018) (9)
Differential effect of L3T4+ cells on recovery from total-body irradiation. (1990) (9)
The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer (2011) (8)
Detection of circulating tumor cells by RT-PCR significantly associated with poor prognosis in breast cancer (2011) (8)
BRCA1 loss pre-existing in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood (2010) (8)
Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay (2020) (8)
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study (2018) (8)
[Diagnosis and clinical significance of disseminated tumor cells in bone marrow]. (2000) (8)
Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells (2015) (8)
Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer (2021) (8)
BM micrometastases and circulating tumor cells in breast cancer patients: where have we been, where are we now and where does the future lie? (2005) (8)
Molecular profiling of micrometastatic cancer cells. (2001) (8)
The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis (2020) (8)
Staging of head and neck cancer. (1995) (7)
Effects of whole body hyperthermia (41.8 degrees C) on the frequency of tumor cells in the peripheral blood of patients with advanced malignancies. (2003) (7)
Down-Regulation and Neo-Expression of Cell Surface Antigens on Individual Micrometastatic Carcinoma Cells (1992) (7)
Persistence of isolated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled analysis. (2009) (7)
Advances in circulating tumor cells (ACTC): from basic research to clinical practice (2013) (7)
Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance. (2022) (7)
Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer: Results of the German SUCCESS trial. (2011) (7)
Circulating MicroRNAs as Non‐Invasive Biomarkers (2013) (6)
Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer (2018) (6)
Differential effect of natural killer cells on modulating CFU-Meg and BFU-E proliferation in situ. (1989) (6)
Circulating Tumor Cells in Head and Neck Carcinomas. (2019) (6)
The DETECT study concept: Individualized therapy of metastatic breast cancer. (2016) (6)
[Prognostic factors in stage I of non-small-cell bronchial carcinoma]. (1996) (6)
Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer (2018) (6)
Loss of 4q21.23-22.1 Is a Prognostic Marker for Disease Free and Overall Survival in Non-Small Cell Lung Cancer (2014) (6)
703 CIRCULATING TUMOR CELLS CAN BE DETECTED IN PATIENTS WITH TESTICULAR GERM CELL TUMORS (2013) (6)
Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer (2021) (6)
Hamburg-Glasgow classification: preoperative staging by combination of disseminated tumour load and systemic inflammation in oesophageal carcinoma (2017) (6)
Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy – translational research program of the German SUCCESS-trial. (2009) (6)
VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma (2012) (6)
Circulating microRNAs as Surrogate Markers for Circulating Tumour Cells and Prognostic Markers in Metastatic Breast Cancer (2012) (6)
A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. (2021) (6)
[The significance of regional lymphatic tumor cell dissemination in patients with resectable non-small cell bronchial carcinoma. Results of a prospective study]. (1995) (5)
1805 Association between HER2-phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer (2015) (5)
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer (2021) (5)
Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors (2003) (5)
Diagnosis and therapeutic relevance of micrometastases. (1998) (5)
Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis (2020) (5)
Increase in Circulating MicroRNA Levels in Blood of Ovarian Cancer Patients (2010) (5)
Lymph node micrometastases in lung cancer. (2007) (5)
Disseminated Epithelial Tumor Cells in Bone Marrow of Patients with Esophageal Cancer: Detection and Prognostic Significance (1996) (5)
Hemodynamic forces tune the arrest, adhesion and extravasation of circulating tumor cells (2017) (5)
A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer. (2020) (5)
REVIEW Detection and Clinical Importance of Micrometastatic Disease (1999) (5)
Inhibition of hematopoietic recovery from radiation-induced myelosuppression by natural killer cells. (1990) (5)
Clinical Utility of Determination of HER-2/neu and EGFR Fragments in Serum of Patients with Metastatic Breast Cancer (2006) (5)
Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells (2021) (5)
Clinical Relevance of Disseminated Tumor Cells in the Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients (2009) (5)
Minimal residual cancer. (1999) (5)
Minimal residual disease and circulating tumor cells in breast cancer: open questions for research. (2012) (5)
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer (2014) (5)
Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments (2021) (5)
Inverse Perfusion Requirements of Supra- and Infratentorial Brain Metastases Formation (2018) (5)
Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial. (2013) (4)
Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer. (2022) (4)
Detection, clinical relevance and specific biological properties of disseminating cancer cells in breast cancer patients. (2009) (4)
[Simultaneous immunocytochemical detection of tumor cells in lymph nodes and in bone marrow of patients with resectable bronchial carcinomas]. (1998) (4)
Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions (2022) (4)
The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy (2020) (4)
Association of persistence of isolated tumor cells (ITC) in bone marrow (BM) of breast cancer patients with risk for relapse. (2004) (4)
Liquid biopsy: from discovery to clinical implementation (2021) (4)
An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer (2014) (4)
Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation (2022) (4)
[Isolated tumor cells in bone marrow predicts reduced survival in lymph node-negative non-small-cell lung cancer]. (2000) (4)
Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence (2021) (4)
Minimal residual disease. Introductory overview. (1999) (4)
High Serum Levels of Wnt Signaling Antagonist Dickkopf-Related Protein 1 Are Associated with Impaired Overall Survival and Recurrence in Esophageal Cancer Patients (2021) (4)
The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer (2020) (4)
Immunocytochemical detection and characterization of individual micrometastatic tumor cells. (2001) (4)
876 PREOPERATIVE DETECTION OF A SINGLE CIRCULATING TUMOUR CELL IS INDEPENDENTLY ASSOCIATED WITH INFERIOR OUTCOME IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER (2012) (4)
Disseminated tumor cells (DTC) in bone marrow (BM) and clinical outcome: Final results of pooled analysis on 10-year survival of 4,703 breast cancer patients (2005) (4)
Bone marrow: Homing organ for dormant micrometastatic cancer cells (2005) (3)
Cancer: A shocking protein complex (2016) (3)
191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells (2012) (3)
Circulating nucleic acids as biomarkers in cancer patients (2012) (3)
Molecular Diagnostics: Going from Strength to Strength (2019) (3)
Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy (2020) (3)
Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma (2022) (3)
TP53 mutations on circulating cell-free DNA (2016) (3)
Tracing the Seeds in the Soil. (2017) (3)
Pathophysiology of Tumor Cell Release into the Circulation and Characterization of CTC. (2020) (3)
ALDH1-positive intratumoral stromal cells indicate epithelial differentiation and good prognosis in prostate cancer (2018) (3)
Circulating tumor cells (CTC) and HER-2 status on CTC and primary tumor in urothelial cancer (UC) patients refractory to platinum based chemotherapy. (2016) (3)
Identification of the c-kit ligand: end of the road for understanding aplastic anemia in steel mutant mice? (1991) (3)
Clinical Studies Plastin 3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial – Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis (2013) (3)
Experimental in vitro, ex vivo and in vivo models in prostate cancer research (2022) (3)
Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study (2021) (3)
Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data (2013) (3)
Persistance of circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after primary diagnosis. (2016) (3)
Cyclophosphamide-induced enhancement of stem cell recovery from whole-body irradiation is radiation dose-dependent. (1989) (3)
Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications (2022) (3)
Potential clinical relevance of micrometastatic breast cancer (1998) (3)
Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors. (2021) (3)
Sensitive Blood-Based Detection of Asbestos-Associated Diseases Using Cysteine-Rich Angiogenic Inducer 61 as Circulating Protein Biomarker. (2020) (3)
Konsensusempfehlungen zu methodischen Aspekten und zur klinischen Relevanz des Nachweises disseminierter Tumorzellen (DTZ) im Knochenmark (KM) von Patientinnen mit primärem Mammakarzinom (2006) (3)
Manuscript Title: Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. (2021) (2)
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation (2022) (2)
The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs). (2015) (2)
Liquid biopsies for surveillance and monitoring treatment response of bladder cancer. (2016) (2)
Circulating Tumor Cells (2020) (2)
[Immunocytochemical detection and prognostic significance of epithelial tumor cells in bone marrow of patients with pancreatic carcinoma]. (1996) (2)
Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Non–Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules (2022) (2)
[Minimal residual disease in breast cancer: detection and clinical relevance]. (2005) (2)
Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation (2022) (2)
Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer. (2021) (2)
Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivo (2022) (2)
Langzeitergebnisse zur prognostischen Bedeutung der Tumorzelldissemination beim Magenkarzinom (1995) (2)
Somatic aberrations of BRCA1 gene are associated with progressive and stem cell-like phenotype of prostate cancer (2018) (2)
Heparan sulfate dependent binding of plasmatic von Willebrand factor to blood circulating melanoma cells attenuates metastasis. (2022) (2)
Prognostic value of bone marrow micrometastasis on disease outcome in 4703 breast cancer patients: meta- and pooled analysis after 10 years of follow-up (2006) (2)
Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer. (2010) (2)
Introductory Overview (2004) (2)
Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow (2022) (2)
Central Mesenteric Lymph Node BER-Ep4+ Cells in Colorectal Cancer: Challenge to Sentinel Node Concept? (2007) (2)
Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value (2023) (2)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben. Berlin, 21.-24. Februar 2018: Abstracts (2018) (2)
Micrometastasis of Epithelial Tumors: Signum Mortis for the Patient or the Achilles’ Heel of Cancer? (1991) (2)
Diverse prognostic value of the GTn promoter polymorphism in squamous cell and adeno carcinoma of the oesophagus (2016) (2)
[Tumor cells in the peripheral blood of patients with urothelial carcinoma of the bladder: detection and impact of circulating]. (2014) (2)
614P Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance (2021) (2)
Persistierende Tumorzellen (PTZ) im Knochenmark von Brustkrebspatientinnen als Surrogatmarker für ein erhöhtes Rezidivrisiko in der onkologischen Nachsorge – Resultate einer europäischen Pooled-Analysis (2005) (2)
Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer (2020) (2)
An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer (2014) (2)
Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells (2022) (2)
Abstract 917: Circulating tumor cells accurately detect and characterize lung cancers in high-risk subjects undergoing low-dose CT screening (2019) (2)
Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker (2022) (2)
Regulation of bone homeostasis by MERTK and TYRO3 (2022) (2)
HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial. (2012) (2)
Abstract OT1-02-04: The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (2017) (2)
Prostate Cancer: Detection of Free Tumor-Specific DNA in Blood and Bone Marrow (2008) (2)
Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis (2018) (1)
Biomarkerforschung in der Krebsfrüherkennung (2012) (1)
Lymphknoten-Mikrometastasierung bei Patienten mit Ösophaguskarzinom (1995) (1)
Microsatellite Analysis in Serum DNA as a Diagnostic Tool for Distinction of Patients With Unknown Pancreatic Masses (2007) (1)
Detection of circulating tumor cells from peripheral blood in prostate cancer (2014) (1)
Prospective Evaluation of Serum HER2 and HER2 Expression on Circulating Tumor Cells in Patients with Metastatic Breast Cancer within the DETECT Study. (2009) (1)
Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data (2021) (1)
Establishment and comparative characterization of two new human esophageal carcinoma cell lines derived from lymph node micrometastatic cells and autologous primary tumor (1998) (1)
Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein (2014) (1)
P36 Persistence of isolated tumor cells (ITC) in bonemarrow (BM) of breast cancer patients predicts increased risk for relapse (2005) (1)
Immunocytochemical detection and characterisation of individual micrometastatic tumour cells. (2012) (1)
Highly efficient capture of circulating tumor cells by microarray in a microfluidic device (2019) (1)
Presence of bone marrow micrometastasis (BMM) in breast cancer patients predicts a poor-prognosis pattern of first distant metastasis: Results from the pooled analysis. (2006) (1)
Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22 (2023) (1)
301 Survival in Early Breast Cancer Patients is Influenced by Circulating Tumor Cells (2012) (1)
Disseminated tumor cells in the bone marrow of ductal carcinoma in situ patients. (2011) (1)
Incidence of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients at primary diagnosis-A potential tool for risk stratification. (2006) (1)
Multicenter study on the detection of disseminated tumor cells in primary breast cancer. (2009) (1)
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients (2016) (1)
The clinical relevance of circulating tumor cells in correlation to other serum biomarkers (VEGF, HER2, EGFR, TIMP1, CAIX, RASp21) in patients with metastatic breast cancer (2018) (1)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients (2015) (1)
Metastasis formation in human solid tumors: phenotypic characteristics of early metastatic cells. (1992) (1)
Liquid Biopsy: Blood-Based Analyses of ctDNA and CTCs. (2021) (1)
Prognostische und therapeutische Bedeutung einzelner disseminierter Tumorzellen in Lymphknoten beim Ösophaguskarzinom (1997) (1)
OT1-02-06: DETECT III – A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2−Negative Metastatic Breast Cancer and HER2−Positive Circulating Tumor Cells. (2011) (1)
Pathogenesis of Minimal Residual Disease: CTCs as Novel Biomarkers in Cancer Disease (2014) (1)
Flüssigbiopsie: Status quo und Zukunftsperspektiven (2017) (1)
Considerations in the development of circulating tumor cell technology for clinical use (2012) (1)
Identification of biologically active cancer cells in blood and bone marrow of cancer patients (2007) (1)
Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells (2015) (1)
Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA. (2018) (1)
Detection of disseminated tumor cells in bone marrow of patients with resectable non-small cell lung cancer (NSCLC) — Long term results after 5 years of follow-up (1997) (1)
Effects of Whole Body Hyperthermia ( 41 . 8 ° C ) on the Frequency of Tumor Cells in the Peripheral Blood of Patients with Advanced Malignancies 1 (2003) (1)
Her2-Expression zirkulierender Tumorzellen bei Patientinnen mit Her2 positivem Mammakarzinom im Frühstadium vor adjuvanter Chemotherapie – Ergebnisse der SUCCESS B Studie (2012) (1)
Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma (2020) (1)
Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy." (2018) (1)
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial (2016) (1)
Metastatic Breast Cancer Recurrence after Bone Fractures (2022) (1)
Prognostische Wertigkeit disseminierter Tumorzellen im Knochenmark von Prostatakarzinompatienten. Veränderung unter endokriner Therapie (2006) (1)
Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study. (2013) (1)
Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients (2022) (1)
Nanoplatforms for Circulating Tumor Cell Detection in Lung Cancer. (2017) (1)
Influence of preoperatively detected circulating tumor cells on the outcome of patients with urothelial carcinoma of the bladder treated with radical cystectomy. (2012) (1)
Circulating microRNAs: promising breast cancer biomarkers - authors' response (2011) (1)
Untersuchungen zum biologischen Potential okkulter Tumorzellen aus einem Lymphknoten eines Patienten mit resektablem Ösophaguskarzinom (1999) (1)
Abstract 4547: Clinical relevance of circulating tumor cells in esophageal cancer (2012) (1)
Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia (2013) (1)
Der Nachweis von isolierten Tumorzellen in Knochenmark und Blut von Patientinnen mit primärem Mammakarzinom - Standardisierte Methodik und klinische Relevanz (2007) (1)
Isolierte Tumorzellen in Knochenmark und Blut von Patientinnen mit primärem Mammakarzinom – Klinische Relevanz (2007) (1)
Abstract 2421: Circulating tumor cells reveal the genetic evolution of metastatic breast cancer (2016) (1)
Abstract OT1-03-05: The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (2018) (1)
Abstract 1826: IMI's CANCER-ID: Status of liquid biopsy standardization (2016) (1)
Abstract OT1-02-02: The DETECT study program – Personalized treatment in metastatic breast cancer based on circulating tumor cells (2016) (1)
MP49-07 THE RISK OF POSTOPERATIVE VENOUS THROMBOEMBOLISM ACCORDING TO THE CIRCULATING TUMOR CELL STATUS IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER TREATED WITH RADICAL CYSTECTOMY (2016) (1)
MP55-02 DO CIRCULATING TUMOR CELLS HELP IN DECISION-MAKING REGARDING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER TREATED WITH RADICAL CYSTECTOMY? (2014) (1)
EPISPOT Assay: Detection of Proteins Secreted by Viable Disseminating Tumor Cells in Solid Tumor Patients (2008) (1)
With one eye on the future. (2022) (1)
Abstract 4960: Molecular characterization of in-vivo isolated EpCAM-positive circulating tumor cells in high-risk prostate cancer patients (2016) (1)
Abstract P2-05-02: Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis (2017) (1)
P4-07-13: Prognostic Impact of Circulating Tumor Cells Assessed with the Cell Search Assay and Adna Test Breast in Metastatic Breast Cancer Patients – The DETECT Study. (2011) (1)
Detection of Disseminated Epithelial Tumor Cells: Methods and Clinical Implications (1999) (1)
Preservation of Biomaterials for translational research in current breast cancer studies: Review and recommendations (2007) (1)
BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant (2014) (1)
Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer. (2012) (1)
Abstract OT3-04-02: DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer (2017) (1)
Detection of Hypomethylation in Long-ctDNA. (2022) (1)
Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape (2020) (1)
Abstract 3403: Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence (2022) (1)
Primary-Tumor-mediated Dormancy of disseminated Breast Cancer Cells in the Bone Marrow due to Down-Regulation of Gas6 (2013) (1)
Abstract PD18-07: Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial (2023) (1)
Immunotherapeutic approaches directed against minimal residual cancer (1995) (1)
Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels (2021) (1)
Circulating Tumor Cells: Detection and Clinical Relevance (2008) (1)
Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain (2021) (1)
International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (1)
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors (2023) (1)
Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma (2022) (1)
EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. (2019) (1)
Possible tumour cell reimplantation during curative endoscopic therapy of superficial Barrett’s carcinoma (2021) (1)
Blood tests for early detection of lung cancer: challenges and promises. (2020) (1)
Correction: Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer (2013) (1)
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. (2016) (1)
Evaluation of the Hamburg-Glasgow Classification in Pancreatic Cancer: Preoperative Staging by Combining Disseminated Tumor Load and Systemic Inflammation (2021) (1)
Abstract 2696: Deciphering the interactome of the metastasis-suppressor protein RAI2 (2018) (1)
Abstract 486: MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes (2018) (1)
Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients (2022) (1)
11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France (2018) (1)
Abstract P2-01-02: Circulating Tumor Cells (CTC) may Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer – Results of the German SUCCESS C Trial (2012) (1)
Cytokeratin (CK)-positive bone marrow micrometastases (BMM) and survival in stage I-III breast cancer (1999) (1)
Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization (2018) (1)
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial. (2021) (1)
Disseminated tumor cells in bone marrow of cancer patients (2015) (1)
Zirkulierende Tumorzellen: Ist die Metastasierung bald vorhersagbar? (2016) (1)
50PENUMERATION AND MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR CELLS IN LUNG CANCER PATIENTS USING THE GILUPI CELLCOLLECTOR™, AN EFFECTIVE IN VIVO DEVICE FOR CAPTURING CTCS (2015) (1)
117 Implications of circulating tumor cells on adjuvant chemotherapy decision-making in patients with urothelial carcinoma of the bladder treated with radical cystectomy (2014) (1)
[Expression of plakoglobin in bronchial carcinomas: incidence and significance for disease outcome]. (1996) (1)
Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer. (2015) (0)
Challenges of research on circulating tumour cells in carcinoma patients (2011) (0)
Abstract B6: Patterns of DNA copy number changes in primary breast cancer and brain metastases (2010) (0)
Detection ofMAGE-ATranscripts in BoneMarrow Is an Independent Prognostic Factor in Operable Non ^ Small-Cell Lung Cancer (2007) (0)
ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing (2021) (0)
Liquid Biopsy to Catch the Epigenetic Changes in Endometrial Cancer. (2022) (0)
IN THE SPOTLIGHT The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer (2012) (0)
617Prostate cancer (PCA) patients display specific genetic alterations in free circulating DNA (2005) (0)
PD32-12 LONG-TERM FOLLOW-UP OF CIRCULATING TUMOR CELLS AS PREDICTORS FOR SURVIVAL IN MEN TREATED WITH ABIRATERONE ACETATE FOR CASTRATION RESISTANT PROSTATE CANCER FOLLOWING CHEMOTHERAPY (2016) (0)
Identification of genes relevant to occult bone marrow micrometastasis in human breast cancer using gene expression profiling (2002) (0)
Opposing prognostic impact of the heme oxygenase-1 promoter polymorphism in complete resected esophageal cancer (2010) (0)
5168 Circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after primary diagnosis – Results from the German SUCCESS trial (2009) (0)
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer (2019) (0)
TEMPORARY REMOVAL: OC-03: Platelet-derived von Willebrand factor is involved in thrombosis and metastatic growth of melanoma in the brain. (2022) (0)
928 CIRCULATING TUMOUR CELLS IN NON-METASTATIC BLADDER CANCER ARE ASSOCIATED WITH WORSE OUTCOME (2010) (0)
Consensus Recommendations on Methodical Aspects and Clinical Relevance of the Evidence of Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer (2007) (0)
Abstract 3253: Mast cell-derived granzyme b contributes to resistance against anti-angiogenic therapy (2016) (0)
Abstracts from the 11th International Symposium on Minimal Residual Disease, 3–5 May 2018, Montpellier, France (2018) (0)
Abstract IA20: Circulating tumor cells: Biology and clinical applications as liquid biopsy (2020) (0)
Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia (2011) (0)
Abstract 3411: Detection and monitoring of tumor-derived mutations in ctDNA using the UltraSEEK Lung Panel on the MassARRAY System in metastatic NSCLC patients (2022) (0)
Immunohistochemical assessment of 17-1A and complement resistance factors CD55 and CD59 in liver metastases of colon cancer (1998) (0)
[Limits of surgery in patients with apparently localized bronchial carcinoma (pT1-3, pN0, M0)]. (1996) (0)
Liquid Biopsy – Ein neues diagnostisches Konzept in der Onkologie (2023) (0)
Abstract PL01-01: Liquid biopsy: Novel technologies and clinical applications (2018) (0)
Relevance of PTEN loss in brain metastasis formation in breast cancer patients (2012) (0)
' s response to reviews Title : Differential regulation of MAGE-A 1 promoter activity by BORIS and Sp 1 , both interacting with the TATA binding protein (2014) (0)
Tumor and Stem Cell Biology De fi nition of Molecular Determinants of Prostate Cancer Cell Bone Extravasation (2013) (0)
Abstract P2-02-15: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer (2018) (0)
Determination of minimal residual disease in solid tumor patients (2001) (0)
Multicenter study on the detection of disseminated tumor cells in primary node-positive breast cancer (2008) (0)
F06Integrin a5 is an independent prognosis factor and a potential therapeutic target for breast cancer bone metastasis (2016) (0)
The dynamic range of circulating tumor DNA in metastatic breast cancer (2014) (0)
Circulating DNA as biomarker in breast cancer (2015) (0)
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing (2013) (0)
Liquid biopsy: blood‐based analyses of circulating cell‐free DNA in xenografts (2022) (0)
A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. (2023) (0)
Integrin α5 is an independent prognosis factor and a potential therapeutic target for breast cancer bone metastasis (2016) (0)
VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma (2012) (0)
Prospective evaluation of genomic aberrations of circulating, cell-free DNA, primary tumor and lymph node metastasis in bladder cancer patients treated with radical cystectomy (2020) (0)
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation (2022) (0)
Reduced expression of pllkoglobin indicates an unfavorable prognosis in patients with esophageal cancer (1998) (0)
292 Methods for detection of circulating tumour cells: potential & limitations (2009) (0)
Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases (2017) (0)
MULTIPLEX LIGATION‐DEPENDENT PROBE AMPLIFICATION OF GENOMIC ABERRATIONS OF CIRCULATING, CELL‐FREE DNA IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY: A PROSPECTIVE STUDY: MP34‐07 (2017) (0)
Detection of isolated carcinoma cells in bone marrow by RT-PCR (2007) (0)
Method for detecting cancer using epithelial cells cytokeratin released as markers for these cells. (2007) (0)
Abstract CT066: Dendritic cell based cryoimmunotherapy associates with clinical variables and changes in T-cell receptor expression in a prospective phase I trial of metastatic castration resistant prostate cancer (2018) (0)
CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent (2016) (0)
Abstract 2165: Genomic profiling of colorectal cancers from patients diagnosed with circulating tumor cells (2010) (0)
Abstract 2219: Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma of the bladder (2019) (0)
Analysis of four human PlGF isoforms and of VEGFR-1 in esophageal carcinoma. (2010) (0)
Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival? (2012) (0)
Abstract 1649: Deadly fuel: Fibroblasts mediate cancer cell death through tunneling nanotubes in response to ionizing radiation (2016) (0)
Author response for "BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer" (2021) (0)
RAI2 as a novel suppressor of cancer cell homing and survival in the bone microenvironment (2022) (0)
Abstract 1571: PTEN is an important mediator of tumor and glia cell crosstalk in breast cancer brain metastasis (2016) (0)
Abstract 3393: Identification of genes mediating early dissemination of tumor cells in breast cancer (2010) (0)
Long-term taxane exposure and transdifferentiation of prostate cancer in vitro. (2023) (0)
Plasticity of disseminating cancer cells in patients with epithelial malignancies (2012) (0)
Prä- und postoperative Detektion zirkulierender Tumorzellen im peripheren Blut von Patientinnen mit Mammakarzinom (2010) (0)
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms (2021) (0)
Prognosis Loss of Heterozygosity at Tumor Suppressor Genes Detectable on FractionatedCirculating Cell-Free TumorDNA as Indicator of Breast Cancer Progression (2012) (0)
Reduced risk of metastatic breast cancer recurrence after bone fractures (2020) (0)
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) (0)
Quantitative Assessment of HER-2/Neu Protein Concentration in Breast Cancer by Enzyme-Linked Immunosorbent Assay (2003) (0)
Profiling circulating tumour cells and other biomarkers of invasive cancers (2018) (0)
Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1. (2023) (0)
Abstract IA18: Circulating tumor cells: Biology and relevance for cancer therapy (2013) (0)
Circulating and Disseminated Tumor Cells from Solid Tumors—Research and Clinical Aspects (2009) (0)
Abstract 2696: EGFR intron-1 CA repeat polymorphism is a predictor of outcome in complete resected only surgically treated esophageal cancer (2010) (0)
Model for Measurement of Micrometastasis in Epithelial Tumours (1993) (0)
Abstract 3610: CANCER ID and the identification of circulating tumor cells (CTCs) in NSCLC (2018) (0)
300 DETECTION OF CIRCULATING TUMOUR CELLS WITH THE CELLSEARCH SYSTEM® IN PERIPHERAL BLOD FROM PATIENTS WITH ADVANCED BLADDER CANCER (2009) (0)
Detection of disseminated tumor cells in the bone marrow and blood of breast cancer patients (2007) (0)
Abstract ED06-03: Circulating tumor cells versus circulating tumor cell products (2013) (0)
917 Detection of disseminated tumour cells in bone marrow of patients with resectable non-small cell lung cancer — Long term results after 5 years of follow-up (1997) (0)
PD51-06 GENOMIC ABERRATIONS OF CIRCULATING, CELL-FREE DNA, PRIMARY TUMOR AND LYMPH NODE METASTASIS IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY (2020) (0)
Circulating Tumor Cells, Heterogeneous PSMA Expression, and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer (2023) (0)
Persistenz zirkulierender Tumorzellen (CTCs) im peripheren Blut zwei Jahre nach Primärdiagnose (2009) (0)
Abstracts des 2. Workshops zur experimentellen und klinischen Kopf-Hals-Onkologie in Lübeck 09.-10.02.2012 (2012) (0)
Zur prognostischen Relevanz des CTC-Status bei Progress des metastasierten Mammakarzinoms (2018) (0)
Die biologische Rolle des Adhäsionsmoleküls ALCAM in Mammakarzinom-Zelllinien und Tumoren (2011) (0)
Das Blutbild von Xenopus laevis als potentieller Indikator für radioaktive Belastung (1990) (0)
Inzidenz zirkulierender Tumorzellen im peripheren Blut (CTC) bei Mammakarzinompatientinnen zum Zeitpunkt der Primärdiagnose – Ein potentieller Marker zur Risikostratifizierung (2006) (0)
Zirkulierende Tumorzellen im peripheren Blut (CTC) beim primären Mammakarzinom – Ein potentieller Marker zur Risikostratifizierung und zum Therapiemonitoring (2006) (0)
1st das nicht-kleinzellige Bronchialcarcinom eine Systemerkrankung? Is Non-small-cell Lung Cancer a Systemic Disease? (1991) (0)
DETECT III und IV - Individualisierte CTC-basierte Therapie des HER2-negativen metastasierten Mammakarzinoms (2020) (0)
Ist das nicht-kleinzellige Bronchialcarcinom eine Systemerkrankung? (1991) (0)
Zirkulierende Tumorzellen im peripheren Blut beim Urothelkarzinom der Harnblase (2014) (0)
Nachweis von Minimal Residual Disease (MRD) im peripheren Blut von Patientinnen mit Brustkrebs – Translationale Forschung in der SUCCESS-Studie (2007) (0)
Prospektive Untersuchung von Serum HER2 in Korrelation mit HER2 Expression auf zirkulierenden Tumorzellen als Teil der DETECT-Studie bei Patientinnen mit metastasiertem Mammakarzinom (2010) (0)
Detektion zirkulierender Tumor- und Endothelzellen unter neoadjuvanter Chemo- und zielgerichteter Therapie – ein translationales Forschungsprojekt der „GeparQuinto„-Studie (2011) (0)
PLAKOGLOBIN DOWNREGULATION ALS INDIKATOR EINER UNGUNSTIGEN PROGNOSE BEI PATIENTEN MIT RESEKTABLEM OSOPHAGUSKARZINOM (1999) (0)
EXPRESSION VON PLAKOGLOBIN BEI BRONCHIALKARZINOMEN: HAUFIGKEIT UND BEDEUTUNG FUR DEN KRANKHEITSVERLAUF (1996) (0)
Detektion zirkulierender Tumorzellen im peripheren Blut beim Prostatakarzinom (2014) (0)
Einfluss HER2-gerichteter Therapien auf den CTC-Status beim metastasierten Mammakarzinom (2019) (0)
Bewertung der prognostischen Bedeutung von zirkulierenden Tumorzellen und deren HER2-Status beim metastasierenden Mammakarzinom (2012) (0)
Nachweis zirkulierender Tumorzellen (CTC) im peripheren Blut von Patientinnen mit primärem Mammakarzinom (2007) (0)
Die Häufigkeit und prognostische Bedeutung der nodalen Mikrometastasierung bei Patienten mit Bronchialkarzinom (1994) (0)
Mechanism of polymerization-induced deactivation of the oncogene CtBP by the oncogene suppressor RAI2 (2022) (0)
Charakterisierung von disseminierten Tumorzellen im Knochenmark beim Mammakarzinom (1991) (0)
Aktuelles zur Liquid Biopsy (2018) (0)
Detektion zirkulierender Tumorzellen im peripheren Blut von HCC-Patienten – eine Pilotstudie (2011) (0)
Erratum zu: Detektion und Stellenwert von zirkulierenden Tumorzellen im peripheren Blut beim Urothelkarzinom der Harnblase (2014) (0)
Prädiktivfaktoren für die Diskrepanz des HER2-Phänotyps zwischen zirkulierenden Tumorzellen und Primärtumor bei Patientinnen mit metastasiertem Mammakarzinom (MBC) (2016) (0)
RESIDUELLE TUMORZELLEN : DIAGNOSTIK& THERAPEUTISCHE STRATEGIEN: ZUSAMMESSSUNG DER ABSTRACTS DES 89TH ANNUAL MEETING DER AMERICAN ASSOCIATION FOR C ANCER RESEARCH (28.3.-1.4.1998, NEW ORLEANS, USA) ZUM THEMENBEREICH (1998) (0)
DETECT V/CHEVENDO - duale HER2-zielgerichteten Therapie mit Trastuzumab und Pertuzumab plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und hormonrezeptor-positivem metastasierten Mammakarzinom (2020) (0)
DETECT V – Expressionsanalyse des human epidermal growth factor receptor 2 und des Estrogenrezeptors auf zirkulierenden Tumorzellen bei Patientinnen mit Metastasiertem Mammakarzinom (2019) (0)
Prognostische Relevanz zirkulierender Tumorzellen (CTCs) im peripheren Blut vor und nach Chemotherapie bei Patientinnen mit primärem Mammakarzinom – Ergebnisse der SUCCESS-Studie (2008) (0)
Minimal Residual Disease (MRD) im peripheren Blut bei Patientinnen mit primärem Mammakarzinom – Translationales Forschungsprogramm der SUCCESS-Studie (2006) (0)
Homing ösophagealer Karzinomzellen in Lymphknoten und ins Knochenmark — Rolle der CXCR4-Expression (2005) (0)
Zur prognostischen Relevanz des CTC-Status bei Progress des metastasierten Mammakarzinoms (2017) (0)
DETECT: Ein prospektiv multizentrischer Vergleich von Methoden zur Bestimmung der HER2-Expression auf disseminierten Tumorzellen aus Blut und Knochenmark – eine Studie der AG Tumorzelldissemination der Senologie (2008) (0)
Nachweis von zirkulierenden Tumorzellen bei Patientinnen mit frühem Brustkrebs fünf Jahre nach adjuvanter Chemotherapie und späte Rezidive – Ergebnisse der SUCCESS A Studie (2018) (0)
DETECT-Studie (Detection of circulating epithelial tumor cells): ein prospektiv multizentrischer Vergleich von Methoden zur Bestimmung der HER2-Expression auf zirkulierenden Tumorzellen beim metastasierten Mammakarzinom (2010) (0)
Zirkulierende Tumorzellen als präoperativer Risikomarker für eine okkulte Metastasierung bei Patienten mit resektablem Cholangiokarzinom (2019) (0)
›› Isolierte Tumorzellen im Knochenmark sagen ein verkürztes Überleben bei lymphknotennegativem nicht-kleinzelligen Bronchialkarzinom vorher 1 (2000) (0)
Expression von Lewis-y-Antigen: Ein Neuer Prognostischer Parameter beim Nicht-kleinzelligen Bronchialkarzinom? (1993) (0)
Nachweis microdisseminierter Tumorzellen im Knochenmark von Patientinnen mit in-situ Karzinomen der Mamma (2008) (0)
Relevanz zirkulierende Tumorzellen (CTCs) vor und nach adjuvanter Chemotherapie – Ergebnisse der SUCCESS-Studie (2010) (0)
Dynamik zirkulierender Tumorzellen unter Chemotherapie und Prognose bei Hochrisiko-Patientinnen mit frühem Mammakarzinom (2016) (0)
Persistenz zirkulierender Tumorzellen direkt nach und zwei Jahre nach adjuvanter Chemotherapie bei Patientinnen mit früher Brustkrebserkrankung – Ergebnisse der SUCCESS Studien (2016) (0)
Metastasiertes kastrationsresistentes Prostatakarzinom (2017) (0)
DETECT III und IV - Individualisierte CTC-basierte Therapie des HER2-negativen metastasierten Mammakarzinoms (2020) (0)
DETECT-Studie (Detection of circulating epithelial tumor cells): Ein prospektiv multizentrischer Vergleich von Methoden zur Bestimmung der HER2-Expression auf disseminierten Tumorzellen aus Blut und Knochenmark (2009) (0)
Serielle Bestimmung von zirkulierenden Tumorzellen (CTC) zur Prädiktion von Therapieansprechen und Prognose beim metastasierten Mammakarzinom (MBC) – eine prospektive Studie an 393 Patientinnen (2014) (0)
Zirkulierende Tumorzellen zur individuellen Therapiekontrolle beim metastasierten Mammakarzinom (2017) (0)
Prognostische Relevanz von CTC-Status und Kinetik bei erneutem Progress des metastasierten Mammakarzinoms (2017) (0)
Prognostische Bedeutung apoptotischer zirkulierender Tumorzellen (aCTCs) bei metastasiertem Mammakarzinom (MBC) (2015) (0)
Präsidentenposter: Kombinierte Tumortherapie gegen Insulin-like growth factor-1 receptor und Her2 als neuartiger Ansatz in der Behandlung von Ösophaguskarzinomen (2009) (0)
Die DETECT-Studien: zirkulierende Tumorzellen (CTC) beim metastasierten Mammakarzinom (MBC) (2015) (0)
Erweiterung des konventionellen Staging durch den Mikrometastasennachweis im Knochenmark von Tumorpatienten (1993) (0)
DETECT V/CHEVENDO – duale HER2-zielgerichteten Therapie mit Trastuzumab und Pertuzumab plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und hormonrezeptor-positivem metastasierten Mammakarzinom (2020) (0)
DETECT V/CHEVENDO – Vergleich der dualen HER2-zielgerichteten Antikörpertherapie in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und Hormonrezeptor-positivem metastasiertem Mammakarzinom (2017) (0)
Ductales Carcinoma in situ: Nachweis disseminierter Tumorzellen im Knochenmark (2011) (0)
MAGE-Expression beim Hepatocellulären Carcinom (HCC) als Ansatzpunkt potentieller adjuvanter Therapieverfahren (2000) (0)
RESIDUELLE TUMORZELLEN: DIAGNOSTISCHE ANSATZE, PROGNOSTISCHE RELEVANZ, BIOLOGIE UND ANTIKORPERTHERAPIE (1999) (0)
DETECT III und IV – Individualisierte CTC-basierte Therapie des metastasierten Mammakarzinoms (2017) (0)
DETECT V – Expressionsnachweis von Estrogenrezeptor und Human Epidermal Growth Factor Receptor 2 in zirkulierenden Tumorzellen bei Patientinnen mit metastasiertem Mammakarzinom (2018) (0)
Die Grenzen der Chirurgie bei Patienten mit einem scheinbar lokalisierten Bronchialkarzinom (pT1–3, pN0, M0) (1996) (0)
Zirkulierende miRNAs als prognostische und prädiktive Marker beim metastasierenden Mammakarzinom (2011) (0)
Serielle Enumeration von CTC zur Prädiktion von Therapieansprechen und Prognose beim metastasierten Mammakarzinom – Analyse der Kinetik intakter und apoptotischer CTC (2014) (0)
Das DETECT-Studienkonzept – Therapie des metastasierten Mammakarzinoms auf der Grundlage zirkulierender Tumorzellen (2016) (0)
Prognostischer Effekt von Änderungen der Anzahl zirkulierender Tumorzellen unter Chemotherapie bei Patientinnen mit frühem Mammakarzinom (EBC) (2016) (0)
Prädiktive Faktoren für die Diskordanz des HER2-Phänotyps zwischen Primärtumor und zirkulierenden Tumorzellen beim metastasierten Mammakarzinom (2016) (0)
Konsensusempfehlungen zur Tumorzelldissemination beim Mammakarzinom (2006) (0)
Prospektive Untersuchung von TIMP-1 (Serum Tissue Inhibitor of Metalloproteinase 1) und CA IX (Carbo-Anhydrase 9) in Korrelation mit zirkulierenden Tumorzellen als Teil der DETECT-Studie bei Patientinnen mit metastasiertem Mamamkarzinom (2010) (0)
Nachweis zirkulierender Tumorzellen (CTC) unter primär systemischer Chemotherapie (PST) im Rahmen der GeparQuattro-Studie (2008) (0)
EpCAM-positive zirkulierende Tumorzellen als möglicher prognostischer Biomarker für ein fortgeschrittenes HCC (2012) (0)
Untersuchungen zur HLA-Klasse-I-Downregulierung bei Weichteilsarkomen mit Expression des tumorspezifischen MAGE-Antigens zur Evaluation eines potentiellen adjuvanten Therapieansatzes (2002) (0)
Expression und prognostische Bedeutung von HLA-Klasse I und II Antigenen, ICAM-1 und des kostimulatorischen Moleküls B7 beim Ösophaguskarzinom (1997) (0)
Erste Ergebnisse aus der randomisierten Phase III Studie DETECT III zur Wirksamkeit des Tyrosinkinaseinhibitors Lapatinib bei der Behandlung von Patientinnen mit HER2-negativem metastasiertem Mammakarzinom und HER2-positiven zirkulierenden Tumorzellen (2021) (0)
Prospektiver Vergleich zweier Methoden zur Bestimmung Zirkulierender Tumorzellen und deren HER2 Expression: Die DETECT-Studie bei Patientinnen mit metastasiertem Mammakarzinom (2011) (0)
Das DETECT-Studienkonzept – Zirkulierende Tumorzellen beim metastasierten Mammakarzinom (2016) (0)
Postmortale Detektion epithelialer Zellen in Knochenmark von Tumor- und Nicht-Tumor-Patienten (2010) (0)
Charakterisierung epithelialer Zellen durch MHC-Klasse-I-Proteine im Knochenmark beim Mammakarzinom (1993) (0)
Schwellenwert-Analyse der CTC-Veränderung unter Therapie zur Definition eines Therapieansprechens beim metastasierten Mammakarzinom (2020) (0)
466Correlation of gene expression and genetic alterations in bladder carcinoma (2005) (0)
The small molecule axl inhibitor BGB324 shows activity against T315I-mutated and BCR-ABL1 wt chronic myeloid leukemia (2014) (0)
Vergleich der Anzahl zirkulierender Tumorzellen mit dem Proliferationsmarker Ki-67 beim metastasierten Mammakarzinom (2018) (0)
303 INVITED Circulating Tumour Cells (2011) (0)
Abstract 1114: Upregulation of ALCAM is a marker for non-small-cell lung cancer brain metastases (2019) (0)
16 Circulating tumour cells (CTCs) can be detected in peripheral blood of breast cancer (BC) patients two years after primary diagnosis (2010) (0)
Consensus Statements for the Detection and Clinical Implementation of Disseminated Tumor Cells in Bone Marrow of Primary Breast Cancer Patients (2006) (0)
The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications (2012) (0)
Abstract PD6-3: Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients (2013) (0)
Circulating Tumor Cells as a Tumor Stage Independent Biomarker for Diagnosis, Prognosis, and Disease-monitoring in Pancreatic Ductal Adenocarcinoma (2021) (0)
Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells (2015) (0)
EP16.01-011 PD-L1 Expression on Cytological Imprints and Circulating Tumor Cells versus Standardized Immunohistochemistry in NSCLC (2022) (0)
Pilot study on liquid biopsies: Are the site of blood draw and pancreatectomy affecting the detectability of CTCs and cfDNA? (2020) (0)
Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B (2017) (0)
Abstract B1: Heme oxygenase-1 transcription controlling GTn repeat polymorphism has contrary prognostic value in squamous cell carcinoma and adenocarcinoma of the esophagus (2010) (0)
The Immunological Basis for the Development of Tumor Cell- and Peptide-Based Vaccines for Treatment of Patients with Renal Cell Carcinoma (1997) (0)
M2058 Prognostic Value of the Heme Oxygenase-1 Transcription Controlling GTn Repeat Promoter Polymorphism in Complete Resected Only Surgically Treated Esophageal Cancer (2010) (0)
Disseminated T umor C ells i n L ymph N odes a s a Determinant f or S urvival i n S urgically R esected Non-Small-Cell L ung C ancer (1999) (0)
Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis (2016) (0)
Survival and ERB-B2 expression of cytokeratin-18 (CK18) bone marrow micrometastases (BMM) in stage I–III breast cancer (1999) (0)
Abstract 5693: Low coverage genome-wide sequencing of cell-free DNA enables detection, therapeutic monitoring, and characterization of copy number alterations in patients with solid tumors (2017) (0)
Abstract 4827: Loss of 11p in primary breast cancer and brain metastases (2011) (0)
Response to Di Cosimo, Torri, and Porcu. (2019) (0)
Abstract SY23-01: Blood-borne tumor cell dissemination in cancer patients (2019) (0)
Use of bone marrow micrometastasis to predict disease-free and overall survival in esophageal cancer: Evaluation of 304 cases. (2009) (0)
Impact of Disseminated Tumor Cells in Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients (2008) (0)
Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer. (2016) (0)
Detection and characterization of disseminated tumor cells present in bone marrow of cancer patients (2008) (0)
Jointly Improving Women’s Health Worldwide – Current Focus of the ‘International Working Group’ of the German Society of Obstetrics and Gynaecology (AG FIDE) (2009) (0)
DETECT V – expression of human epidermal growth factor receptor 2 and estrogen receptor on circulating tumor cells of metastatic breast cancer patients (2018) (0)
Tumorzellnachweis im Knochenmark und Blut von Patientinnen mit Mammakarzinom: Klinisches Potenzial, Studienergebnisse und aktuelle Forschungsprojekte in Deutschland (2007) (0)
903 Circulating tumour cells can not predict clinical or nodal stage, but survival after radical cystectomy for urothelial carcinoma of the bladder (2012) (0)
PROCEEDINGS OF THE 16th INTERNATIONAL HAMBURG SYMPOSIUM ON TUMOR MARKERS (2016) (0)
Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer (2018) (0)
Abstract 1716: GSTP1 promoter methylation in in-vivoisolated CTCs from high-risk prostate cancer patients (2017) (0)
Receptor discordance between primary tumor and metastasis influences CTC-status (2020) (0)
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. (2006) (0)
Abstract 5596: Impact of blood collection tubes on CTC-, ctDNA- and miRNA recoveries in malignant melanoma patients (2018) (0)
Detection of Isolated Tumor Cells in Bone Marrow and Peripheral Blood of Breast Cancer Patients - Standardising the Method and Looking for Clinical Relevance (2007) (0)
Abstract 117: The transcription factor iroquois homeobox 2 (IRX2) is a candidate metastasis suppressor that acts as regulator of cellular motility and chemokine expression in breast cancer cells (2014) (0)
Establishment of immunocytochemical and molecular methods for characterization of circulating tumor cells in breast cancer patients (2007) (0)
CirculatingTumor Cells and BoneMarrowMicrometastasis (2008) (0)
The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma (2020) (0)
107 Evaluation of circulating tumor cells to predict metastatic progression in men treated with abirateron acetat for castration resistant prostate cancer: A sub-analysis of the German named patient program (2013) (0)
Abstract 267: Xenograft models of non-metastatic non-small cell lung cancer reveals micrometastasis-associated single cell composition (2022) (0)
Abstract OT3-18-01: Detect III/IV study trial - The multicenter study program in patients with HER2-negative MBC and circulating tumor cells (2020) (0)
Micrometastatic Disease Transcription-Polymerase Chain Reaction for Diagnosis of Disseminated Tumor Cells : A Novel Multimarker Reverse Genes in Occult MAGE-A Heterogeneous Expression of Updated Version (2001) (0)
Circulating tumor-macrophage fusion cells as stage independent, unfavourable, prognostic markers in Pancreatic Ductal Adenocarcinoma (2022) (0)
11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France (2018) (0)
Abstract 503: Molecular characterization ofin vivoisolated EpCAM-positive circulating tumor cells in breast cancer: Table 1. (2016) (0)
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) (0)
[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data]. (2018) (0)
Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial (2018) (0)
Abstract PS2-02: Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) (0)
Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC). (2013) (0)
651 Circulating tumor cells predict oncological outcomes in patients with pure urothelial carcinoma and variant urothelial carcinoma histology after radical cystectomy (2015) (0)
Abstract 6688: Development of a liquid biopsy cfDNA assay for detection of multiple HPV types in cervical neoplasias (2023) (0)
32PMolecular characterization of breast cancer brain metastases and circulating tumor cells (2015) (0)
Profiling Circulating Tumour Cells and Biomarkers of Invasive Cancers (2018) (0)
Abstract 3099: Role of the transcription factor iroquois homeobox 2 (IRX2)in breast cancer progression and metastasis (2011) (0)
Abstract P3-01-04: DETECT V – Expression analysis of human epidermal growth factor receptor 2 and estrogen receptor on circulating tumor cells of metastatic breast cancer patients (2019) (0)
EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients (2019) (0)
Commentary Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives (2004) (0)
Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC). (2013) (0)
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016) (0)
Detect-Study: Comparison of Two Techniques for the Evaluation of the HER2 Expression on Circulating Tumor Cells in Metastatic Breast Cancer. (2009) (0)
Erratum to: Current role of liquid biopsy in metastatic breast cancer and future perspectives (2016) (0)
Imaging , Diagnosis , Prognosis Loss of Heterozygosity at Tumor Suppressor Genes Detectable on FractionatedCirculating Cell-Free TumorDNA as Indicator of Breast Cancer Progression (2012) (0)
Epithelial-mesenchymal plasticity in circulating tumor cells (2016) (0)
Abstract 3190: Standardization and clinical implementation of liquid biopsy assays - IMI's CANCER-ID (2019) (0)
The combination of EpCAM-positive circulating tumor cells and serum AFP levels predicts early recurrence after resection of hepatocellular carcinoma (2023) (0)
Comparison of two CTC enrichment methods in primary and metastatic breast cancer patients (2009) (0)
Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients – translational research program of the German SUCCESS-Trial (2008) (0)
1096 Molecular signatures of disseminated tumour cells in metastatic breast cancer patients (2009) (0)
Abstract 3724: RAI2 controls polycomb-mediated repression of CDKN1A by its interaction with CtBP1 (2023) (0)
917 Prevalence and prognostic value of circulating tumor cells in blood of patients with localized prostate cancer prior to radical prostatectomy (2012) (0)
Klinische Bedeutung des Nachweises minimaler Residualerkrankung bei Leukämien, Lymphomen und soliden Tumoren (2006) (0)
144P A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer (2021) (0)
Clonality of circulating tumor cells in breast cancer brain metastasis patients (2019) (0)
Abstract 3370: Liquid biopsy approaches to determine tumor cell heterogeneity in advanced prostate cancer (2023) (0)
Biology of Human Tumors Circulating Tumor Cells in Patients with Testicular Germ Cell Tumors (2014) (0)
Occult T umor C ells i n B one M arrow o f P atients W ith Locoregionally R estricted O varian C ancer P redict E arly Distant M etastatic R elapse (2001) (0)
Clinical Relevance of Early Disseminated Breast Cancer Cells Depends on Their Cytokeratin Expression Pattern. (2009) (0)
Relevance of circulating and disseminated tumor cells of patients with squamous cell carcinoma of the oral cavity (2013) (0)
Prognostic Impact of Perineural, Blood and Lymph Vessel Invasion for Esophageal Cancer Patients (2012) (0)
Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma (2022) (0)
Advances in circulating tumor cells (ACTC): from basic research to clinical practice (2013) (0)
Prognostic Value of Preoperative Circulating Tumor Cell Counts in Patients with UICC-Stage I-IV Colorectal Cancer (2020) (0)
Speaker Abstracts (2012) (0)
Dynamic MicroRNA-Expression in Plasma of Melanoma Patients Correlates with Progression, PD-L1 Status and Overall Survival (2022) (0)
Abstract 3528: Genotype discordance between circulating tumor cells in blood and disseminated tumor cells in bone marrow at single cell level in breast cancer patients (2014) (0)
Use of Axl, a therapeutic target in AML, to mediate stroma-induced chemoresistance. (2013) (0)
Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy (2003) (0)
Abstract 1295: RAI2 is a novel bone metastasis-associated gene, mediating a vicious cross talk between breast cancer cells and osteoclasts (2023) (0)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a study in 107 patients (2014) (0)
In Situ Detection andQuantification of ARV 7 , AR-FL , PSA , and KRAS Point Mutations in Circulating Tumor Cells (2018) (0)
OC-0493 CTCs in patients with brain metastases under radiotherapy: do they indicate treatment response? (2019) (0)
BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia (2015) (0)
2001 ORAL Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients – Results from the translational research program of the German SUCCESS-Trial (2007) (0)
Detection of circulating glioblastoma cells in peripheral blood (2015) (0)
954 EVALUATION OF CIRCULATING TUMOR CELLS TO PREDICT METASTATIC PROGRESSION IN MEN TREATED WITH ABIRATERON ACETAT FOR CASTRATION RESISTANT PROSTATE CANCER: A SUB-ANALYSIS OF THE GERMAN NAMED PATIENT PROGRAM (2012) (0)
MP58-10 THE ASSOCIATION OF CIRCULATING TUMOR CELLS AND VARIANT HISTOLOGY ON OUTCOMES IN UROTHELIAL CARCINOMA OF THE BLADDER TREATED WITH RADICAL CYSTECTOMY (2015) (0)
Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer. (2022) (0)
Five plus three for the pancreas. (2023) (0)
Abstract 2733: Novel function of the RAI2 protein in genomic integrity of breast cancer cells (2016) (0)
Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer (2017) (0)
89PRelevance of βß-Gal-ß-GalNAc-containing O-glycans and the enzymes involved in their synthesis for vascular and lymphatic invasion and survival in breast cancer patients (2015) (0)
12 . LYMPH NODE MICROMETASTASES IN LUNG CANCER (2007) (0)
P2.06-039 Searching for Standards: Multicenter Ring Trials to Evaluate Technologies for the Enrichment of Circulating Tumor Cells: Topic: LAB, Other (2017) (0)
Abstract OT2-01-03: DETECT V - Comparison of dual HER2-targeted therapy with trastuzumab and pertuzumab plus CDK4/6 inhibition in combination with either chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (2020) (0)
Immunohistochemical assessment of 17-1A and complement resistance factors CD55 and CD59 in esophageal cancer (1998) (0)
Early tumour cell dissemination in non-small cell lung cancer (1994) (0)
CXCR7 expression in esophageal cancer (2013) (0)
Abstracts from the 11th International Symposium on Minimal Residual Disease, 3–5 May 2018, Montpellier, France (2018) (0)
Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients (2018) (0)
Maligner Phänotyp immunhistochemisch detektierbarer isolierter Zellen in den Lymphknoten von Patienten mit Ösophaguskarzinom (2000) (0)
Abstract 1189: MERTK is a target in the microenviroenment of osteolytic bone metastasis (2023) (0)
[Liquid Biopsy - A new diagnostic concept in oncology]. (2023) (0)
Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer (2018) (0)
Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations (2022) (0)
Abstract 3786: Multicenter evaluation of technology platforms for the enumeration of circulating tumor cells (2017) (0)
Polymer pen lithography for biosensing and biomedical applications (2016) (0)
Abstract 1167: The GNAS1 T393C polymorphism is a predictor of clinical outcome in esophageal cancer (2010) (0)
Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases (2018) (0)
Evaluation of bone marrow: Prediction of outcome and response (2003) (0)
Abstract P3-01-23: Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2- breast cancer: Implications for treatment of ER+/HER2- breast cancer (2019) (0)
Characterization of the HER2 status on circulating breast cancer cells. (2009) (0)
Consensus Statement on Mandatory Registration of Clinical Trials (2007) (0)
Abstract P2-02-06: Impact of apoptotic circulating tumor cells in metastatic breast cancer (2016) (0)
Macrophage Stimulating 1 Receptor (2011) (0)
1062 PRESENCE OF CIRCULATING TUMOUR CELLS IN NON-METASTATIC BLADDER CANCER IS AN INDEPENDENT RISK FACTOR FOR WORSE OUTCOME (2011) (0)
Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients (2022) (0)
Abstract 3985: Dynamic changes of tumor-derived extracellular vesicles and related RNAs in blood samples of NSCLC patients (2019) (0)
Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model. (2023) (0)
Abstract 3736: Role of RAI2 protein in progression of breast and prostate cancer to hormone independent disease (2018) (0)
1350 PRESENCE OF DISSEMINATED TUMOR CELLS AT TIME OF RADICAL PROSTATECTOMY IS NOT ASSOCIATED WITH MORE ADVANCED OR POORLY DIFFERENTIATED DISEASE IN PATIENTS WITH LOCALIZED PROSTATE CANCER; POTENTIAL SOURCES OF RELAPSE? (2013) (0)
Preclinical models to study patient-derived circulating tumor cells and metastasis. (2023) (0)
Abstract 46: Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients (2014) (0)
Detection and characterization of circulating microsatellite-DNA and tumor cells in bone marrow in non-metastatic breast (2006) (0)
Characterisation of micrometastatic tumor cells (2000) (0)
The role of disseminated tumour cells and circulating tumour cells in the early development of (bone) metastasis (2010) (0)
Abstract CN02-01: Circulating tumor cells as targets for cancer therapy (2009) (0)
Circulating Tumor Cells in Breast Cancer : Correlation to Bone MarrowMicrometastases , Heterogeneous Response to Systemic Therapy and Low ProliferativeActivity (2005) (0)
Abstract P1-13-09: Withdrawn (2018) (0)
MP78-06 THE EFFECT OF CIRCULATING TUMOR CELLS AND COPY NUMBER VARIATIONS OF CIRCULATING TUMOR DNA ON SURVIVAL IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY (2018) (0)
Human Micrometastases Solid Epithelial Tumors : Establishment of Working Models for Disseminated Cancer Cells in Bone Marrow of Patients with Phenotypic Characteristics of Cell Lines Derived from Updated (1998) (0)
Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma (2022) (0)
761 Micrometastases in lymph nodes in urological tumours (2003) (0)
Detection of Circulating Plasma Cells in Multiple Myeloma. (2017) (0)
Dendritic cell (DC) based cryoimmunotherapy (CryoIT) in a prospective phase I trial of metastatic castration resistant prostate cancer (mCRPC): Interim analysis. (2018) (0)
EP-1708: Clinical relevance of DNA-damage response in metastatic breast and lung cancer under irradiation (2018) (0)
Expression of the melanoma antigen-encoding gene in hepatocellular carcinoma (2000) (0)
Molecular phenotyping of minimal residual disease in solid cancer – Defining the markers for tumor progression? (2006) (0)
P4-07-14: Circulating Tumor Cells (CTCs) Detection and HER2 Profiling by CellSearch® in Non-Metastatic Breast Cancer: An International Ring Study To Assess Inter-Reader Variability. (2011) (0)
730Prostate cancer (PCA) patients display significant higher plasma levels of cell- free DNA (2005) (0)
O43. Circulating tumour cells (CTCs) in patients suffering from SCC of the oral cavity (2011) (0)
Monoclonal Antibody Therapy with Edrecolomab in Breast Cancer Patients : Monitoring of Elimination of Disseminated Cytokeratin-positive Tumor Cells in Bone Marrow 1 (1999) (0)
Micrometastatic cells as targets for adjuvant therapies (2004) (0)
Breast cancer brain metastases: biology and new clinical perspectives (2016) (0)
1413: Detection and Comparison of free Cellular DNA Levels in Plasma of BPH and Prostate Cancer Patients (2005) (0)
281PCell-free circulating DNA as independent prognostic markers in metastatic breast cancer (2017) (0)
RNF40-dependent epigenetic regulation of actin cytoskeletal dynamics is required for HER2-driven mammary tumorigenesis (2020) (0)
Current role of liquid biopsy in metastatic breast cancer and future perspectives (2016) (0)
Axl, a therapeutic target in AML mediates stroma-induced chemoresistance (2013) (0)
Abstract 1161: COX-2 blockade improves efficacy of VEGF-targeting drugs (2014) (0)
Abstract 1447: Retinoic acid-induced 2 driven polymerization of c-terminal binding proteins sustains epithelial differentiation in castration-resistant prostate cancer (2023) (0)
Standardization and clinical implementation of liquid biopsy assays - IMI's CANCER-ID (2019) (0)
Abstract PD04-08: Circulating tumor cells (CTC) in peripheral blood of breast cancer patients two years after adjuvant chemotherapy depending on endocrine treatment — The German SUCCESS-Trial (2010) (0)
Identification of Target Genes in Micrometastatic Lung Cancer by Methylation Arrays (2008) (0)
961 CIRCULATING TUMOUR CELLS IN NON-METASTATIC BLADDER CANCER ARE ASSOCIATED WITH WORSE OUTCOME (2010) (0)
Abstract P2-01-07: Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach (2022) (0)
Detection of minimal residual disease (MRD) in peripheral blood of primary breast cancer patients: Translational research in the SUCCESS study (2007) (0)
100INTHE POTENTIAL OF CIRCULATING TUMOUR CELLS AS A LIQUID BIOPSY TO GUIDE THERAPY IN PROSTATE CANCER. (2014) (0)
802 Presence of disseminated tumor cells at time of radical prostatectomy is not associated with more advanced or poorly differentiated disease in patients with localized prostate cancer; potential sources of relapse? (2013) (0)
Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer (2016) (0)
Imaging , Diagnosis , Prognosis PrognosticRelevanceofCirculatingTumorCells inBloodand Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity (2013) (0)
Cancer Metastasis: Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients (2011) (0)
Abstract #LB-280: Expression of early placenta insulin-like growth factor in breast cancer a prerequisite of metastasis forming disseminated tumor cells? (2009) (0)
Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients (2023) (0)
Abstract 5581: Clinical validation of a highly sensitive assay to detect mutations in plasma from advanced lung adenocarcinoma patients (2018) (0)
293 Characterisation and monitoring of circulating tumour cells (2009) (0)
328 Jagged1 expression and its relevance in metastatic progression of breast cancers (2014) (0)
Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN) (2018) (0)
Detection of circulating lymphendothelial cells in patients with solid tumors. (2006) (0)
Circulating tumor cells and copy number variations of circulating tumor DNA in bladder cancer patients treated with radical cystectomy (2018) (0)
Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer (2023) (0)
Abstract P1-01-03: Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients – Results from the adjuvant SUCCESS A trial (2017) (0)
Abstract 1604: IMI CANCER-ID: Validation of novel blood-based biomarker technologies in clinical settings (2015) (0)
breast cancer: a prospective, multicenter trial (2011) (0)
Abstract 3364: RAI2 maintains genome stability of breast cancer cells (2018) (0)
Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes (2018) (0)
Abstract IA15: Biology and clinical implications of circulating tumor cells and bone marrow micrometastasis (2013) (0)
Author Correction: Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases (2020) (0)
Advances in liquid biopsy approaches for early detection and monitoring of cancer (2018) (0)
Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC) (2013) (0)
63 Circulating Metastasis-initiating Cells in Breast Cancer (2012) (0)
Genetic traits for hematogeneous tumor cell dissemination in cancer patients (2016) (0)
Abstract CN3-1: Detection, clinical relevance, and molecular characteristics of circulating tumor cells (2010) (0)
Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients (2014) (0)
CTCBC – Recognition of Tumor Cells in Breast Cancer by using Clustering Methods (2016) (0)
Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans (2022) (0)
Author Correction: Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases (2020) (0)
COMPARISON OF RT-PCR AND IMMUNOCYTOCHEMISTRY FOR THE DETECTION OF DISSEMINATED TUMOR CELLS IN BONE MARROW AND BLOOD OF PATIENTS WITH PROSTATE CANCER (1999) (0)
Detection of minimal residual disease in predicting outcome (2008) (0)
Abstract P4-01-08: Persistence of circulating tumor cells immediately after and two years after systemic adjuvant chemotherapy in patients with early breast cancer – Results of the German SUCCESS trials (2015) (0)
Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients (2019) (0)
Characterization of genomic aberrations of circulating, cell-free DNA in bladder cancer patients treated with radical cystectomy using multiplex ligation-dependent probe amplification: A new and efficient profiling method (2017) (0)
Influence of preoperatively detected circulating tumor cells on the outcome of patients with urothelial carcinoma of the bladder treated with radical cystectomy. (2012) (0)
Abstract 1579: IMI's CANCER-ID: Implications of liquid biopsy technology standardization for its clinical use (2018) (0)
Characterization of circulating DNA in plasma of patients after allogeneic bone grafting (2019) (0)
23 A comparative study of Tissue Inhibitor of Metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer (2008) (0)
BI-25CIRCULATING TUMOR CELLS IN GLIOBLASTOMA (2014) (0)
Simultaner immunzytochemischer Nachweis von Tumorzellen in Lymphknoten und im Knochenmark von Patienten mit resektablen Bronchialkarzinomen Simultaneous immunocytochemical detection of tumor cells in lymph nodes and bone morrow of patients with resectable lung cancer (1998) (0)
Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC) (2020) (0)
367 Genomic profiles of single tumour cells in metastatic breast cancer patients (2010) (0)
Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses (2022) (0)
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. (2023) (0)
Destruction of autologous tumor cells following treatment of cancer patients with murine monoclonal antibody SDZ ABL 364 (1991) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Klaus Pantel?

Klaus Pantel is affiliated with the following schools:

University of Bonn
TU Dresden
Medical University of Graz
University of Bergen
University of Erlangen–Nuremberg
University of Cologne
Ludwig Maximilian University of Munich
Heinrich Heine University Düsseldorf
University of Twente
Federal University of Rio de Janeiro
University of Hamburg

Klaus Pantel's Academic­Influence.com Rankings

Why Is Klaus Pantel Influential?

Klaus Pantel's Published Works

Published Works

What Schools Are Affiliated With Klaus Pantel?

Klaus Pantel's AcademicInfluence.com Rankings